#1
|
||||
|
||||
åñòü ðàçíûå âèäû - ÷èòàéòå ñàìè
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#2
|
||||
|
||||
êàê ïîíèìàþ, äëÿ äàííûõ ìóòàöèé õàðàêòåðíû íèçêèé Ò4 è âûñîêèé Ò3, ó ðåáåíêà ÷òî â àíàëèçàõ?
low serum T4 and high serum T3 levels (and thus an elevated T3/T4 ratio), growth retardation, delayed mental and bone development, and constipation
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#3
|
|||
|
|||
Ò4 íà íèæíåé ãðàíèöå íîðìû, à Ò3 íèêîãäà íå íàçíà÷àëè. Äèàãíîç îò ýíäîêðèíîëîãà-"ãèïîòèðîêñèíåìèÿ", ãîðìîíû íå íàçíà÷àþò. Ïî îïèñàíèþ î÷åíü ïîõîæå, ýíäîêðèíîëîãè äî òîãî, êàê âèäåëè àíàëèç êðîâè, ãîâîðèëè, ÷òî ÂÃÒ ñòî ïðîöåíòîâ, íî ÒÒà âñåãäà â íîðìå áûë
|
#4
|
||||
|
||||
òòã ó äåòåé ñ äàííîé ìóòàöèåé â íîðìå, âàì íóæíî ïîëó÷èòü çàî÷íóþ êîíñóëüòàöèþ â åíäîêðèí. öåíòðå Ìîñêâû
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#5
|
|||
|
|||
Çäðàâñòâóéòå! Ñåãîäíÿ ñäåëàëà äî÷åðè àíàëèç íà ãîðìîíû ÙÆ-òàì è ïðàâäà ò3 ïîâûøåí, à ò4 ïîíèæåí.
|
#6
|
||||
|
||||
âîò òèïè÷íûå íàõîäêè ó ïàöèåíòà ñ äå-íîâî ìóòàöèåé, ïîõîæèå íà âàøåãî ðåáåíêà, ñ ó÷åòîì èõ íîðì - âûäåëåíî ìíîé:
A de novo heterozygous missense mutation in the THRA gene (c.767T>C), resulting in substitution of Thr for Met at codon 256 (p.M256T), was identified in a 19-year-old male patient presenting with features similar to previously reported RTHα patients, including disproportionate ischial leg length (sitting height to height ratio +2.5 SD score), mild neurodevelopmental delay, coarse facies, macrocephaly (head circumference 60 cm, +2.5 SD score), and high serum T3/T4 ratio with normal TSH concentrations: FT4, 10.6 pmol/L (normal range, 11 to 25 pmol/L); total T4, 67 nmol/L (normal range, 58 to 128 nmol/L); total T3, 2.9 nmol/L (normal range, 1.4 to 2.5 nmol/L); reverse T3, 0.18 nmol/L (normal range, 0.22 to 0.54 nmol/L); T3/T4 ratio, 0.043 (normal range, 0.01 to 0.03); and TSH, 1.83 mU/L (normal range, 0.4 to 4.3 mU/L)] This mutation is not present in public databases (dbSNP, 1000Genome, and Exome Aggregation Consortium).
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#7
|
||||
|
||||
è ïîæàëóéñòà, êàê ìîæíî ñêîðåå ïîëó÷èòå êîíñóëüòàöèþ ñïåöèàëèñòà, ñêîðåå âñåãî âàø ðåáåíîê äîëæåí ïîëó÷àòü òèðîêñèí, êîòîðûé ïîìîæåò óñòðàíèòü íåêîòîðûå ïðîáëåìû ñî çäîðîâüåì;
íèæå ôðàãìåíò î ðåáåíêå èç Èçðàèëÿ, ó êîòîðîé äèàãíîç ïîñòàâëåí â 10 ìåñ., òîæå íîâàÿ ìóòàöèÿ î÷åíü áëèçêà ïî ðàñïîëîæåíèþ êàê ó âàøåãî ðåáåíêà: 400 ïîçèöèÿ , à íèæå 380-ÿ, ëå÷åíèå ñîïðîâîæäàåòñÿ íîðìàëèçàöèåé ò4/ò3, íî óìåíüøåíèåì ÒÒÒ íèæå íîðìû, íî ýòî íîðìàëüíî äëÿ äåòåé ñ ìóòàöèåé - âûäåëåíî ìíîé: A de novo heterozygous THRA gene mutation was identified (c1139delG; pC380SfsX9), affecting only the α1 subunit of the TRalpha protein. TFTs at 10 months of age presented an elevated T3/T4 ratio, and low total T4 levels. Levothyroxine (LT4) treatment for 10 months produced an appropriate rise in total T4, total T3, and free T3 levels as well as a suppressed TSH (<0.01 mU/L). However, the T3/T4 ratio decreased from 46 at baseline to 31. Peripheral tissue markers of TH action demonstrated an expected decrease of serum cholesterol from 310 to 100 mmol/L and creatine kinase that decreased from 297 to 70 IU/L. Paradoxically, sex hormone binding globulin and ferritin levels also decreased 67% and 22%, respectively. As previously reported in other patients with RTHa, the child had significant normocytic anemia with a hemoglobin of 9.0 g/L, which did not change throughout the course of LT4 treatment (9.1 g/L at 20.8 months of age).
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#8
|
||||
|
||||
ß çàæåëòèëà ëè÷íûå äàííûå, è ñîâåòóþ îáðàòèòñÿ ñ ïðîñüáîé î êðíñóëüòàöèè ëèáî ê íàì â ÍÌÈÖ ýíäîêðèíîëîãèè ( èíñòèòóò äåòñêîé ýíäîêðèíîëîãèè) , ëèáî â ÍÌÈÖ ãåíåòèêè ( äìí Òþëüïàêîâ ÀÍ);
__________________
Ã.À. Ìåëüíè÷åíêî |
#9
|
|||
|
|||
Çäðàâñòâóéòå! Ãàëèíà Àôàíàñüåâíà, íå ìîãëè áû Âû ìíå îòâåòèòü íà âîïðîñû ïî ïîâîäó î÷íîé êîíñóëüòàöèè ýíäîêðèíîëîãà, ìíå î÷åíü âàæíî Âàøå ìíåíèå. Ãåíåòèê ìåíÿ îòïðàâèëà ê çàâåäóþùåìó ýíäîêðèíîëîãè÷åñêèì îòäåëåíèåì áîëüíèöû, îò êîòîðîé îòïðàâëÿëè ìåäèöèíñêèå äîêóìåíòû äëÿ ïîëíîãåíîìíîãî ñåêâåíèðîâàíèÿ. Îí íà îñìîòðå ñêàçàë, ÷òî ñèìïòîìàòèêà, ôåíîòèï ó äî÷êè âðîæä¸ííîãî ãèïîòèðåîçà, íî òòã â íîðìå, åé óæå 6 ëåò, ó íå¸ ãðóáîå íàðóøåíèå ðàçâèòèÿ è íå èìååò ñìûñëà å¸ â Ìîñêâó îòïðàâëÿòü. ß ïîïðîñèëà êîíñóëüòàöèþ ïî òåëåìåäèöèíå, îí îáåùàë ñ êîëëåãàìè ñîçâîíèòüñÿ. Ñåãîäíÿ îòâåòèë, ÷òî êîëëåãè èç Ìîñêâû ñ íèì ñîëèäàðíû, â 6 ëåò íè÷åãî íå èçìåíèòü, ïðè ýòîì âðà÷ íàçíà÷èë äî÷êå íà ìåñÿö 25 ìã ýóòèðîêñà, ïî åãî ñëîâàì, ïîñìîòðåòü, êàê ïîâëèÿåò íà àíàëèç êðîâè.
Åñòü ëè âîçìîæíîñòü óëó÷øèòü ñîñòîÿíèå ðåáåíêà èëè òàêîå íå ëå÷èòñÿ? Èìååò ëè ñìûñë äàâàòü åé ýóòèðîêñ? Ïîìîã áû îí åé, åñëè áû åãî íàçíà÷èëè äî âîçðàñòà îäíîãî ãîäà (òòã ó íå¸ âñåãäà áûë â íîðìå)?ß íå ïîíèìàþ-ñ îäíîé ñòîðîíû, ìíå ãîâîðÿò, ÷òî àíàëèçû íà ãîðìîíû õîðîøèå, ñ äðóãîé-÷òî íàäî áûëî ýóòèðîêñ íàçíà÷àòü ðàíüøå(. |
#10
|
||||
|
||||
Öèòàòà:
Âàì äîëæåí áûòü ïðåäñòàâëåí òåêñò çàî÷íîé êîíñóëüòàöèè
__________________
Ã.À. Ìåëüíè÷åíêî |
#11
|
|||
|
|||
Çäðàâñòâóéòå, óâàæàåìûå êîíñóëüòàíòû ôîðóìà! Ñïàñèáî Âàì çà Âàø òðóä, ïîìîùü â óñòàíîâëåíèè äèàãíîçà. Ìû ñ äî÷êîé ïðîëåæàëè â ÝÍÖ, äèàãíîç "ñèíäðîì ðåçèñòåíòíîñòè ê òèðåîèäíûì ãîðìîíàì" ïîäòâåðäèëñÿ. È õîòÿ âðà÷ ãîâîðèò, ÷òî ñëîæíî ñêàçàòü, áóäåò ëè êàêîé-òî ýôôåêò îò òèðîêñèíà, çà ìåñÿöû åãî ïðè¸ìà ó ðåá¸íêà ïîÿâèëèñü ïîäâèæêè â ðå÷è, îíà ëó÷øå õîäèò, ñòàëà âûíîñëèâåå(ðàíüøå íà óëèöå íå ìîãëà äîëãî õîäèòü, ïîñòîÿííî ñàäèëàñü îòäûõàòü íà ñêàìåéêå), âñ¸ ýòî îòìå÷àþò è å¸ äåôôåêòîëîãè, ëîãîïåä(ÿ èì íå ãîâîðèëà, ÷òî íà÷àëè ïðèíèìàòü òèðîêñèí).  îáùåì, äàæå ìèíèìàëüíûå óëó÷øåíèÿ-ýòî îãðîìíàÿ ðàäîñòü äëÿ ìåíÿ.
|
#12
|
||||
|
||||
Óñïåõîâ!
__________________
Ã.À. Ìåëüíè÷åíêî |